3,3-diphenyl-propylamine; hydrochloride | 1019-05-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,3-diphenyl-propylamine; hydrochloride
• 英文别名: 3,3-Diphenylpropan-1-amine;hydron;chloride；3,3-diphenylpropan-1-amine;hydron;chloride
• CAS: 1019-05-2
• 化学式: C₁₅H₁₇N*ClH
• 分子量: 247.768
• InChiKey: AHHLKJBLNXAJID-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.59
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3,3-diphenyl-propylamine; hydrochloride 在 Rh on carbon 氢气 作用下， 以 乙醇 为溶剂， 反应 20.0h， 以100%的产率得到3,3-dicyclohexyl-1-propanamine hydrochloride
  参考文献：
  名称：

  Synthesis and histamine H2 agonistic activity of arpromidine analogues: replacement of the pheniramine-like moiety by non-heterocyclic groups

  摘要：

  Analogues of the potent histamine H-2 agonist arpromidine, characterized by non-heterocyclic groups (phenyl, cyclo-hexyl, alkyl) instead of the pheniramine-like portion, were prepared and tested for their H-2 agonistic and H-1 antagonistic activity in the isolated guinea pig right atrium and ileum, respectively. In the diphenylpropylguanidine series an increase in H-2 agonistic potency resulted from mono- or difluorination at one or both phenyl rings in the meta and/or para position (pD2 less-than-or-equal-to 7.75 vs pD2 = 7.15 for the unsubstituted parent compound). Compounds chlorinated at both phenyl rings were considerably less potent. Highest combined H-2 agonistic/H-1 antagonistic potency was found in the 4-fluorophenyl series. The arpromidine analogue with cyclohexyl and methyl group instead of phenyl and pyridine ring proved to be 30 times more potent than histamine in the atrium. The H-1 antagonistic potency in cyclohexyl compounds was lower than in the diaryl series. Thus, aromatic rings appear not to be required for high H-2 agonistic potency but are useful for combined H-2 agonistic/H-1 antagonistic activity.

  DOI：

  10.1016/0223-5234(92)90145-q
• 作为产物：
  描述：

  缺甲心可定 在 盐酸 、 palladium 10% on activated carbon 、 氢气 作用下， 以 乙醇 、 水 为溶剂， 反应 14.0h， 生成 3,3-diphenyl-propylamine; hydrochloride
  参考文献：
  名称：

  借用氢方法将醇转化为N保护的伯胺并进行原位脱保护

  摘要：

  醇已被转化为一系列受保护的胺，包括磺酰胺和N-烷基苄基胺衍生物。还提供了脱保护以提供伯胺的代表性实例。

  DOI：

  10.1016/j.tetlet.2009.02.129
• 作为试剂：
  描述：

  3-(2,2-Diphenylethyl)-4,5-dihydro-5-oxo-1,2,4-oxadiazol-4-essigsaeure-ethylester 在 盐酸 、 sodium hydroxide 、 3,3-diphenyl-propylamine; hydrochloride 、 N,N'-二环己基碳二亚胺 作用下， 以 吡啶 、 苯 为溶剂， 反应 13.0h， 生成 N-(3,3-Diphenylpropyl)-2-<<1-(hydroxyimino)-3,3-diphenylpropyl>amino>acetamid
  参考文献：
  名称：

  Ajzert, K. Ilona; Takacs, Kalman, Chemische Berichte, 1984, vol. 117, # 10, p. 2999 - 3003

  摘要：

  DOI：

文献信息

• [EN] NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS<br/>[FR] COMPOSES UTILES POUR LE TRAITEMENT DE L'OBESITE, DU DIABETE DE TYPE II ET DES TROUBLES DU SYSTEME NERVEUX CENTRAL
  申请人：BIOVITRUM AB

  公开号：WO2004000828A1

  公开（公告）日：2003-12-31

  The present invention relates to compounds of the general formula (I), wherein P is sulfone or sulfonamide; and A, B, W, X, Y and R3 are as defined in the description;to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes, and/or CNS disorders, to achieve reduction of body weight and of body weight gain.

  本发明涉及一般式（I）的化合物，其中P为砜或磺酰胺；A、B、W、X、Y和R3如描述中定义；含有这些化合物的药物组合物；以及利用这些化合物预防和治疗与肥胖、2型糖尿病和/或中枢神经系统疾病有关的医疗状况，以实现减轻体重和减少体重增加。
• [EN] SUBSTITUTED DIARYLALKYL AMIDES AS CALCIUM CHANNEL ANTAGONISTS<br/>[FR] AMIDES DE DIARYLALKYLE SUBSTITUES EN TANT QU'ANTAGONISTES DE CANAUX CALCIQUES
  申请人：WARNER-LAMBERT COMPANY

  公开号：WO1999055688A1

  公开（公告）日：1999-11-04

  (EN) The present invention provides compounds that block calcium channels and have Formula (I). The present invention also provides pharmaceutical compositions containing the compounds of Formula (I) and methods of using them to treat stroke, cerebral ischemia, head trauma, and epilepsy.(FR) L'invention concerne des composés de formule (I) inhibant les canaux calciques. L'invention concerne également des compositions pharmaceutiques renfermant les composés de formule (I) et leurs procédés d'utilisation pour traiter les accidents cérébrovasculaires, l'ischémie cérébrale, des traumatismes crâniens et l'épilepsie.

  本发明提供了一种阻断钙通道的化合物，其具有公式（I）。本发明还提供了含有公式（I）化合物的药物组合物以及使用它们治疗中风、脑缺血、头部创伤和癫痫的方法。
• New compounds
  申请人：——

  公开号：US20040024210A1

  公开（公告）日：2004-02-05

  The present invention relates to compounds of the general formula (I), 1 wherein P is sulfone or sulfonamide; and A, B, W, X, Y and R 3 are as defined in the description; to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes, and/or CNS disorders, to achieve reduction of body weight and of body weight gain.

  本发明涉及一般式(I)的化合物，其中P是磺酮或磺酰胺；A、B、W、X、Y和R3如描述中所定义；以及包含这些化合物的药物组合物，以及使用这些化合物预防和治疗与肥胖、2型糖尿病和/或中枢神经系统疾病相关的医疗状况，以实现减轻体重和减缓体重增加。
• Tetrahydronaphthalenols for the treatment of hypertension
  申请人：E.R. Squibb & Sons, Inc.

  公开号：EP0163458A1

  公开（公告）日：1985-12-04

  New compounds, useful for the treatment of hyperten- sion, have the formula and pharmaceutically acceptable salts thereof, wherein R, is hydrogen or methyl; R2 is hydrogen, alkyl, alkanoyl, or arylcarbonyl; R3 and R4 are each aryl; R3 and R4 are each cycloalkyl; R3 is hydrogen or alkyl and R4 is cycloalkyl or 9H-fluoren-9-yl; or R3 is hydrogen or alkyl and R4 is heteroaryl; R5 and R6 are the same or different and each is hydrogen, hydroxy, alkoxy or alkanoyl; and n is 1, 2, 3 and 4.

  可用于治疗高血压的新化合物具有如下式及其药学上可接受的盐，其中 R, 是氢或甲基；R2 是氢、烷基、烷酰基或芳羰基；R3 和 R4 各自是芳基；R3 和 R4 各自是环烷基；R3 是氢或烷基，R4 是环烷基或 9H-芴 -9- 基；或 R3 是氢或烷基，R4 是杂芳基；R5 和 R6 相同或不同，各自是氢、羟基、烷氧基或烷酰基；n 是 1、2、3 和 4。
• N6- substituted diarylalkyl adenosines, processes for their production and pharmaceutical compositions comprising the same
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0251339A2

  公开（公告）日：1988-01-07

  N⁶-Substituted diarylalkyladenosines of the formula: are disclosed. Processes for their manufacture and pharmaceutical compositions containing the same are also disclosed. The compounds have highly desirable central-nervous system and cardio-vascular properties.

  本发明公开了式：的 N⁶-取代二芳基烷基腺苷，还公开了其生产工艺和含有这些化合物的药物组合物。 这些化合物具有非常理想的中枢神经系统和心血管特性。